Congratulations to the inaugural AIM-HI Women’s Venture Competition finalists selected by the Judging Committee, Stacy Blain of Concarlo Holdings and Manijeh Goldberg of Privo Technologies. Not only are they advancing science, but they are also paving the way for more…
It’s 2020, and still only 2.2% of all venture capital dollars go to companies led by women entrepreneurs in life sciences. Let’s change that! Join us on Thursday, September 24, at the AIM-HI Women’s Venture Competition Award Ceremony as we celebrate…
Serial entrepreneur Ken Malone, Ph.D., and his team of scientists and business executives are at the forefront of developing cutting-edge biohealth companies. Malone is the Chairman of the Board of Directors of Rasio Therapeutics, a start-up which is bringing innovative…
The 8 semi-finalists are just announced in the AIM-HI Accelerator Fund's inaugural Women’s Venture Competition! These innovative oncology startups are selected from an exceptional pool of high quality women entrepreneur applications, by a Selection Committee comprised of world-class key opinion…
Imran Alibhai, Ph.D., is the CEO of Tvardi Therapeutics, a biopharmaceutical company developing breakthrough medicines for diverse cancers, chronic inflammatory diseases and fibrotic diseases. The National Foundation for Cancer Research and AIM-HI Accelerator Fund have been early financial supporters of…
Tvardi Therapeutics Inc., a privately held, clinical-stage biopharmaceutical portfolio company of the AIM-HI Accelerator Fund focused on the development of STAT3 inhibitors, announced today over $5 million in non-dilutive grants to support the ongoing validation and clinical development of its…
Paul B. Fisher, M.Ph., Ph.D., co-founded InterLeukin Combinatorial Therapies with hopes of developing a product that destabilizes and kills cancer cells. The Director of Virginia Commonwealth University’s Institute of Molecular Medicine, Fisher represents a world-class scientist with knowledge also of…
Rose Wang is a serial entrepreneur who helps other individuals and teams—including female cancer researchers—start their own businesses and make them thrive. Wang is the founder of Binary Group, a consulting and business solutions firm. She also currently serves as Executive…
The National Foundation for Cancer Research is a "special organization," says Charlie Weatherspoon, Co-founder and Chairman of the Board of the AIM-HI Accelerator Fund (AIM-HI), which has a strong relationship with NFCR. Weatherspoon contrasts the grassroots efforts at NFCR and…
We are doing a randomized multi-center international clinical trial with a target population of hepatitis B virus-associated hepatocellular carcinoma. In order to develop PHY906 as a drug, we formed a company called Yiviva, in which Yale is a co-founder… Read…
